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Connecting channels develop between maternal myo-
metrial spiral arteries and lacunae in the wall of the
implanted cytoblast. After connecting to the maternal
circulation, exposure to allergens or antigens can
occur and can stimulate an immune response in the
developing fetus. The exact mechanism of how anti-
gens cross from the maternal to fetal circulation is
not fully understood. There is evidence that transpla-
cental antigen transfer occurs as immune complexes
via receptor-mediated transport across the syncytio-
trophoblastic membrane and endothelium of vessels
in fetal villi (1) (Figure 1). In order to protect from pre-
natal antigens, maternal immunoglobulin G (IgG) anti-
bodies can, via placental transfer, reach the fetus to
provide protection to the infant while his/her humoral
response is inefﬁcient. Interestingly, IgG seems to be
the only antibody class that signiﬁcantly crosses the
human placenta, a process that is facilitated by the
neonatal Fc receptor (FcRn) for IgG. Furthermore, ﬁ-
broblasts and Hofbauer cells (i.e., placental macro-
phages) are found in the villous stroma and are
presumably involved in the binding and trapping of
immune complexes (1). In this regard, it is interesting
to note that the anti-SSA/Ro or SSB/La antibodies
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may induce damage to the fetus, leading to neonatal
lupus (NL).
Cardiac manifestations of NL include advanced
condition defects and occasionally cardiomyopathy
with a high morbidity and mortality rate. In this
regard, a study by Ismirly et al. (3), which included
325 offspring exposed to maternal anti-SSA/Ro anti-
bodies presenting with NL, showed a case fatality rate
of 17%, with one-third of the cases dying in utero
and a high post-natal mortality rate, too, because
survival at 10 years for children born alive was >85%,
with the majority of deaths occurring within the
ﬁrst year of birth.In this issue of the Journal, the same team, this
time led by Saxena et al. (4), report performing
a carefully conducted, complex study presenting
the ﬁrst evidence of maternal passively transferred
autoimmunity. Subjects were identiﬁed by the
U.S. Research Registry for Neonatal Lupus, which
enrolled mothers with anti-SSA/Ro and/or SSB/La
antibodies and having at least 1 child with NL.
Maternal and cord blood in cases with cardiac NL
or unaffected pregnancies were compared. Plasma
markers of inﬂammation, cardiac performance, and
ﬁbrosis were correlated using a rigorous score for
fetal outcome. In total, cord blood was obtained from
139 anti-SSA/Ro–exposed fetuses, 42% (n ¼ 59) with
cardiac NL, and 54% (n ¼ 75) without NL. Because the
plasma markers for fetal reactive inﬂammatory and
ﬁbrotic components were elevated in anti-SSA/
Ro–exposed fetuses, the authors conclude that they
are possibly contributing to the development of car-
diac neonatal lupus. A control group of fetuses not
exposed to SSA/Ro and/or SSB/La antibodies was not
included. This is regrettable because it would have
FIGURE 1 IgG Transfer
Scheme adapted from Palmeira et al. (1) showing immunoglobulin G (IgG) transfer from the
mother to the fetus during pregnancy across the syncytiotrophoblasts of the placenta.
Maternal IgG or IgM antibodies such as anti-SSA/Ro or anti-SSB/La are internalized at the
maternal side of syncytiotrophoblasts membrane and collected in endosomes that express
the neonatal Fc receptor (FcRn) at their surface. These IgG antibodies bind to the FcRn in
the endosome, which protects them from degradation by lysosomal enzymes in the
acidiﬁed endosomal milieu. Subsequently, the endosomes are transported to the fetal side
of the syncytiotrophoblast and fuse with the fetal side of the membrane. This leads to
exposure at physiological pH, which promotes the release of these maternal IgG antibodies
into the fetal circulation, a feature that subsequently may promote neonatal lupus.
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values of the markers measured.
This is the largest repository reported from neo-
nates exposed to maternal autoantibodies supporting
the role of tissue inﬂammation in the pathogenesis
and morbidity of cardiac NL. However, as the authors
correctly speculate, other factors such as fetal reac-
tivity and the in utero environment also are likely to
contribute, because the estimated risk of cardiac NL
is approximately 2%, and about 10% when following
previously affected pregnancies in SSA/Ro antibody–
positive women (3).
It is important to note that placental transfer of
maternal IgG antibodies to the fetus provides pro-
tection to the infant whose own immune response
is inefﬁcient (2). Interestingly, SSA/Ro antibodies
largely belong to the IgG antibody class, which is
actively transmitted by the FcRn receptor system
expressed on syncytiotrophoblast cells from the
maternal circulation to the fetus (2), a feature that
may explain why fetuses from SSA/Ro and/or SSB/La
antibody–positive mothers have a higher risk of NL.
An observation in the present study is that troponin-I
levels are not elevated in cord blood fromNL neonates.
Interestingly, anti-SSA/Ro and anti-SSB/La antibodies
have been shown by Clancy et al. (5) to induce car-
diomyocyte apoptosis. Because apoptosis is a con-
trolled pathway of cell death, it may not lead to a
substantial release of cardiomyocyte proteins. The
study by Clancy et al. (5) also notes that the subsequent
phagocytosis of apoptotic cardiomyocytes, that natu-
rally would take place, may be blocked, leading to
inﬂammation, scarring, and ﬁbrosis, features that are
typically observed in cardiac NL.
There is evidence from a few other studies that
cord blood can be used for early detection of neonatal
cardiovascular disease. Llurba et al. (6) reported on
impairment in angiogenic biomarkers in maternal
and cord blood associated with fetal congenital heart
disease (CHD). Interestingly, in the plasma of women
pregnant with a fetus with a major congenital heart
disease, the antiangiogenic vascular endothelial
growth factor receptor (VEGF) 1, also called soluble
fms-like tyrosine kinase 1 (sFlt-1), was signiﬁcantly
higher. The interlinked, platelet-derived, proangio-
genic factor placental growth factor (PIGF) was sig-
niﬁcantly lower. Fetuses with CHD also had higher
cord blood levels of sFlt-1 and soluble engolin.
Examination of the heart tissue from the fetuses
with CHD showed a signiﬁcant increase in markers of
chronic hypoxia and antioxidant activity, as well as
expression of VEGF and sFlt-1. The study also showed
maternal serum PIGF being decreased and sFLt-1
increased at 18 to 37 weeks gestation, suggestingimpairment in placental angiogenesis. The authors,
therefore, speculate that placental hypoxia due to
abnormal angiogenesis may cause fetal hypoxia,
leading to abnormal heart development and low birth
weight. Based on those and other observations, the
term cardio-placental syndrome has been postulated
(7). A study by Loukovaara et al. (8), demonstrated
that in serum taken from cord blood at birth in
pregnancies complicated by type 1 diabetes and
hypertensive disorders, fetal hypoxia (measured by,
for instance, amniotic erythropoetin and umbilical
gas variables) was associated with elevated cord
serum C-reactive protein levels. Hypoxia itself causes
overproduction of sFlt-1 that could activate a cycle
wherein high sFlt-1 levels inhibits angiogenesis and
exacerbates placental hypoxia (7).
In conclusion, so far, only a few studies have
analyzed the interrelation of maternal and cord-blood
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942serum biomarkers of inﬂammation, angiogenesis, and
ﬁbrosis, neonatal birth weight, and fetal and post-
natal disease such as NL. Among them, this new
study by Saxena et al. (4) provides signiﬁcant evidence
for a relationship between fetal and maternal bio-
markers in women with maternal systemic lupus ery-
thematosus. In addition, their study emphasizes a high
predictive value of cord-blood serum for NL, a feature
that should be explored in future studies, not only for
NL, but also for the presence of other (cardiovascular)disease types, thereby allowing early detection and
better management of fetal and post-natal disease.
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